MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 412993 | Name: CK 3579

Description:

WARNING: This product is for research use only, not for human or veterinary use.

CK 3579 is an antiarrhythmic and electrophysiologic biochemical.

Chemical Structure

CK 3579
CK 3579
CAS#128264-20-0

Theoretical Analysis

MedKoo Cat#: 412993

Name: CK 3579

CAS#: 128264-20-0

Chemical Formula: C21H26N4O5S

Exact Mass: 446.1624

Molecular Weight: 446.52

Elemental Analysis: C, 56.49; H, 5.87; N, 12.55; O, 17.92; S, 7.18

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
CK 3579; CK3579; CK-3579; CK 4000; CK4000; CK-4000; HE93; HE-93; HE 93
IUPAC/Chemical Name
(+-)-N-(4-(2-Hydroxy-3-((2-(4-(1H-imidazol-1-yl)phenoxy)ethyl)amino)propoxy)phenyl)methanesulfonamide
InChi Key
QZWUQVSQIFFFKY-UHFFFAOYSA-N
InChi Code
InChI=1S/C21H26N4O5S/c1-31(27,28)24-17-2-6-21(7-3-17)30-15-19(26)14-22-11-13-29-20-8-4-18(5-9-20)25-12-10-23-16-25/h2-10,12,16,19,22,24,26H,11,13-15H2,1H3
SMILES Code
CS(=O)(NC1=CC=C(OCC(O)CNCCOC2=CC=C(N3C=CN=C3)C=C2)C=C1)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 446.52 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Argentieri TM, Troy HH, Carroll MS, Doroshuk CM, Sullivan ME. Electrophysiologic activity and antiarrhythmic efficacy of CK-3579, a new class III antiarrhythmic agent with beta-adrenergic blocking properties. J Cardiovasc Pharmacol. 1993 Apr;21(4):647-55. doi: 10.1097/00005344-199304000-00020. PMID: 7681912. 2: Chi LG, Mu DX, Driscoll EM, Lucchesi BR. Antiarrhythmic and electrophysiologic actions of CK-3579 and sematilide in a conscious canine model of sudden coronary death. J Cardiovasc Pharmacol. 1990 Aug;16(2):312-24. doi: 10.1097/00005344-199008000-00019. PMID: 1697389. 3: Beatch GN, Dickenson DR, Tang AS. Effects of optical enantiomers CK-4000(S) and CK-4001(R) on defibrillation and enhancement of shock-induced extension of action potential duration. J Cardiovasc Electrophysiol. 1995 Sep;6(9):716-28. doi: 10.1111/j.1540-8167.1995.tb00448.x. PMID: 8556192. 4: Lee K, Park JY, Ryu PD, Kwon LS, Kim HY. IKr channel blockers: novel antiarrhythmic agents. Curr Med Chem Cardiovasc Hematol Agents. 2003 Oct;1(3):203-23. doi: 10.2174/1568016033477414. PMID: 15326913. 5: Lombardi F, Terranova P. Pharmacological treatment of atrial fibrillation: mechanisms of action and efficacy of class III drugs. Curr Med Chem. 2006;13(14):1635-53. doi: 10.2174/092986706777441940. PMID: 16787210. 6: Riera AR, Uchida AH, Ferreira C, Ferreira Filho C, Schapachnik E, Dubner S, Zhang L, Moffa PJ. Relationship among amiodarone, new class III antiarrhythmics, miscellaneous agents and acquired long QT syndrome. Cardiol J. 2008;15(3):209-19. PMID: 18651412. 7: Camm AJ, Yap YG. What should we expect from the next generation of antiarrhythmic drugs? J Cardiovasc Electrophysiol. 1999 Feb;10(2):307-17. doi: 10.1111/j.1540-8167.1999.tb00676.x. PMID: 10090237. 8: Adamson PB, Vanoli E, Hull SS, Foreman RD, Schwartz PJ. Antifibrillatory efficacy of ersentilide, a novel beta-adrenergic and Ikr blocker, in conscious dogs with a healed myocardial infarction. Cardiovasc Res. 1998 Oct;40(1):56-63. doi: 10.1016/s0008-6363(98)00137-0. PMID: 9876317. 9: Morgan TK Jr, Lis R, Lumma WC Jr, Wohl RA, Nickisch K, Phillips GB, Lind JM, Lampe JW, Di Meo SV, Reiser HJ, et al. Synthesis and pharmacological studies of N-[4-[2-hydroxy-3-[[2-[4-(1H-imidazol-1- yl)phenoxy]ethyl]amino]propoxy]phenyl]methanesulfonamide, a novel antiarrhythmic agent with class II and class III activities. J Med Chem. 1990 Apr;33(4):1087-90. doi: 10.1021/jm00166a002. PMID: 2319556. 10: Lee JH, Rosenshtraukh L, Beloshapko G, Rosen MR. The electrophysiologic effects of ersentilide on canine hearts. Eur J Pharmacol. 1995 Oct 4;285(1):25-35. doi: 10.1016/0014-2999(95)00359-s. PMID: 8846808.

View History

Soclenicant

Soclenicant